🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just got to #ASCO24. Will share my thoughts on GU abstracts and presentations soon.

Here’s a social media post I’d like to see: “This year at Pharma corp, we decided to contribute our #ASCO24 meeting advertising budget to patient assistance programs, so your patients will have easier financial access to our medication. Therefore, you will not see our drug name

The big news in advanced urothelial (bladder) cancer at #ASCO24 isn’t at #ASCO24. Press release just dropped that the phase 3 trial to confirm that #sacituzumab govitecan (SG) improves overall survival in late stage disease compared to old standard of care chemotherapy was

Fascinating preliminary phase I trial data in metastatic castrate resistant prostate cancer (mCRPC): #ASCO24 abstract 5061 – EZH2 inhibitor #mevrometostat (mevro) + enzalutamide (enza) in prior abiraterone or enza treated patients. The median radiographic progression free

Another interesting new compound in advanced prostate cancer: ODM-209. #ASCO24 abstract 5060: Prelim results from dose escalation phase 1 study. This is a novel CYP11A1 inhibitor, which blocks production of steroid hormones. 34 patients with metastatic castrate resistant

What was the best part of the oral prostate cancer session at #ASCO24 yesterday? When an audience member asked why a control arm inferior to the standard of care was used in the randomized clinical trial being discussed. Let me explain: ARPI = abiraterone, enzalutamide,

ARV-766: another interesting new drug for metastatic castrate resistant prostate cancer (mCRPC) with promising early phase data presented at #ASCO24. ARV-766 is an AR "PROTAC," a molecule that enhances degradation of the androgen receptor (AR) inside of prostate cancer cells.

Bipolar androgen therapy (BAT) for advanced prostate cancer: I am an advocate in the appropriate patient setting based on the TRANSFORMER study. TRANSFORMER results and protocol: pubmed.ncbi.nlm.nih.gov/33617303/ Unfortunately we don't know in advance which patients are most likely to

Here are questions someone should ask me when I make a treatment recommendation: 1. How much experience do you have with my situation? 2. What are all my current treatment options? 3. If I have more than one option, what are the pros and cons of each? 4. What are the a) most

Another interesting drug in development for advanced prostate cancer to watch: FOR46. FOR46 is an antibody-drug conjugate that binds a tumor-specific epitope of CD46 on prostate cancer cells. Prelim activity from a phase I study combining FOR46 with enzalutamide in metastatic

Is it possible to predict which men with newly diagnosed metastatic prostate cancer are likely to respond the best to treatment and live the longest? Yes. Depth of PSA response to initial therapy is prognostic of patient outcome. This has been observed across multiple trials

Key question for the use of enfortumab vedotin (Padcev) in patients with advanced urothelial (bladder) cancer: If I have to reduce the dose for side effects in someone who is responding to the drug, will it compromise the tumor response? Probably not. That's what was observed

Any promising biomarkers that may tell us which patients should receive adjuvant immunotherapy after surgical removal of a local kidney cancer? Yes! KIM-1. #ASCO24 abstract 4506: In a trial of patients who received immunotherapy (atezolizumab) after surgery to lower risk of

Is it a good idea to take turmeric (curcumin) or other herbal supplements to treat cancer? This is one of the most common questions I get. I have a few questions about this myself: First, how do you know what you're putting in your mouth is actually what it says on the bottle?

For men with metastatic prostate cancer who are taking abiraterone and prednisone: When your PSA level starts to rise, that indicates the emergence of growing, resistant cancer cells. Did you know that switching prednisone to dexamethasone (but continuing abiraterone) might

Want new information for men with metastatic prostate cancer? Our results from the ENZADA trial for men with advanced prostate cancer are now published! We studied the treatment combination of enzalutamide (Xtandi) with androgen deprivation therapy (ADT) and chemotherapy

Looking ahead to the most interesting prostate cancer clinical trial results to be presented at the ASCO annual meeting in a week….. The AMPLITUDE trial of niraparib (parp inhibitor) + abiraterone in HRR-altered metastatic castrate-sensitive prostate cancer is going to be